Injectable Options as Add-Ons to Basal Insulin: Targeting PPG

in Type 2 Diabetes Patients

Program Goals

The Incretin System: Response to Oral Glucose

Injected Incretin-based Agents: GLP-1 Receptor Agonists

Oral Incretin-based Agents: DPP-4 Inhibitors

Main Pathophysiological Defects in T2D

T2D Anti-Hyperglycemic Therapy: General Recommendations

Approaches to Intensifying Therapy in Patients Not At Goal on Basal

Insulin

Adding Prandial Insulin to Basal Insulin: Key Challenges

Scientific Rationale for Combining Basal Insulin with a GLP-1 agonist

DPP- 4 Inhibitors as Add-ons to Basal Insulin

Pramlintide as Add-on to Basal Insulin

Twice-daily Exenatide as Add-on to Basal Insulin (Glargine)

Twice-daily Exenatide as Add-on to Basal Insulin (Glargine): Results

Metformin plus Liraglutide Followed by Add-on of Basal

Insulin (Detemir)

Metformin plus Liraglutide Followed by Add-on of Basal

Insulin (Detemir)

Oral Agents Plus Basal Insulin (Glargine) Followed by Add-on Lixisenatide*

Oral Agents Plus Basal Insulin (Glargine) Followed by Add-on Lixisenatide* (cont)

Other Safety Concerns With GLP-1 Receptor Agonists

Lixisenatide* vs Liraglutide: Effect on Postprandial Glucose Levels†

Comparison of Basal Insulin + Lixisenatide* and Basal-Plus

Regimensa

IDegLira* vs Degludec* or Liraglutide Alone: Effect on HbA1c

IDegLira* vs Degludec* or Liraglutide Alone: Results

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)